Citi Upgrades Illumina, Quest, Agilent to Buy, Downgrades Avantor
Oppenheimer's Top SMID Ideas Within High-growth Themes
Drug Middlemen Pay Higher Prices to Their Own Pharmacies, Says FTC
(July 9): Drug middlemen paid their own mail-order pharmacies as much as 200 times more than the price at rival pharmacies for commonly prescribed cancer drugs, allowing them to bring in at least US$1 billion (RM4.71 billion) in excess revenue and potentially raising the costs to patients, the US Federal Trade Commission (FTC) found in an interim study.
Here's What to Expect From Labcorp Holdings' Next Earnings Report
Laboratory Corp. Price Target Raised to $215.00/Share From $210.00 by Evercore ISI Group
Laboratory Corp. Price Target Raised to $215.00/Share From $210.00 by Evercore ISI
Laboratory Corp. Is Maintained at In-Line by Evercore ISI Group
Laboratory Corp. Is Maintained at In-Line by Evercore ISI
Evercore ISI Adjusts Price Target on Laboratory Corp of America Holdings to $215 From $210
Laboratory Corp of America Holdings (LH) has an average outperform rating and a price target range of $210 to $262, according to analysts polled by Capital IQ.Price: 191.00, Change: -11.96, Percent
NOWDiagnostics Secures $22.5 Million in Series B Funding
New investment will accelerate the development and expansion of rapid at-home diagnostic solutions, bolstering NOWDx's position as a visionary in the industry NOWDiagnostics, Inc. (NOWDx), a developer of
Labcorp Holdings Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)
In the last three months, 6 analysts have published ratings on Labcorp Holdings (NYSE:LH), offering a diverse range of perspectives from bullish to bearish.The table below summarizes their recent rati
Laboratory Corp. Is Maintained at Outperform by Baird
Laboratory Corp. Is Maintained at Outperform by Baird
Laboratory Corp. Price Target Raised to $261.00/Share From $258.00 by Baird
Laboratory Corp. Price Target Raised to $261.00/Share From $258.00 by Baird
Labcorp Holdings Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/08/2024 27.58% Baird $258 → $261 Maintains Outperform 06/13/2024 26.11% Baird $256 → $258 Maintains Out
Baird Maintains Labcorp Holdings(LH.US) With Buy Rating, Raises Target Price to $261
Baird analyst Eric Coldwell maintains $Labcorp Holdings(LH.US)$ with a buy rating, and adjusts the target price from $258 to $261.According to TipRanks data, the analyst has a success rate of 52.5%
Quest Diagnostics' LifeLabs Buy Could Boost Earnings by 4% to 5% -- Market Talk
1145 ET - Quest Diagnostics acquiring LifeLabs could be 4% to 5% accretive to its earnings in fiscal 2025, UBS analysts say, assuming the lab-test provider grows 5% annually and Quest uses a fairly eq
Baird Raises Price Target on Laboratory Corp of America to $261 From $258
Laboratory Corp of America Holdings (LH) has an average rating of outperform and price targets ranging from $210 to $262, according to analysts polled by Capital IQ. Price: 204.20, Change: +0.34, Perc
Labcorp to Announce Second Quarter Financial Results on August 1, 2024
BURLINGTON, N.C., July 1, 2024 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, will release its financial results for the second quarter of 20
The Past Three Years for Labcorp Holdings (NYSE:LH) Investors Has Not Been Profitable
Many investors define successful investing as beating the market average over the long term. But the risk of stock picking is that you will likely buy under-performing companies. We regret to report
Is Labcorp Holdings Inc. (NYSE:LH) Potentially Undervalued?
Express News | Labcorp Launches Global Trial Connect For Increasing Speed Of Clinical Trials
Express News | Labcorp Launches Global Trial Connect to Accelerate Clinical Trials